ValuEngine upgraded shares of Revance Therapeutics (NASDAQ:RVNC) from a sell rating to a hold rating in a research note published on Friday morning.
Other equities research analysts have also recently issued reports about the stock. Cantor Fitzgerald set a $50.00 price target on shares of Revance Therapeutics and gave the company a buy rating in a research report on Wednesday, November 29th. Mizuho reissued a buy rating and issued a $54.00 price target on shares of Revance Therapeutics in a research report on Friday, January 5th. Piper Jaffray Companies boosted their price target on shares of Revance Therapeutics from $28.00 to $51.00 and gave the company an overweight rating in a research report on Tuesday, December 5th. Barclays set a $40.00 price target on shares of Revance Therapeutics and gave the company a buy rating in a research report on Tuesday, December 19th. Finally, Cowen set a $55.00 price target on shares of Revance Therapeutics and gave the company a buy rating in a research report on Wednesday, January 17th. Four equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. The stock currently has a consensus rating of Buy and a consensus price target of $44.30.
Shares of Revance Therapeutics (NASDAQ:RVNC) opened at $30.00 on Friday. The stock has a market cap of $929.14, a price-to-earnings ratio of -7.87 and a beta of 1.36. Revance Therapeutics has a 1 year low of $18.00 and a 1 year high of $37.45.
In related news, CEO L Daniel Browne sold 7,600 shares of the business’s stock in a transaction on Wednesday, November 22nd. The shares were sold at an average price of $24.94, for a total value of $189,544.00. Following the completion of the sale, the chief executive officer now directly owns 133,188 shares of the company’s stock, valued at $3,321,708.72. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. 18.86% of the stock is owned by insiders.
A number of hedge funds and other institutional investors have recently bought and sold shares of RVNC. SG Americas Securities LLC acquired a new position in Revance Therapeutics in the third quarter valued at $144,000. Legal & General Group Plc increased its stake in Revance Therapeutics by 8.1% in the second quarter. Legal & General Group Plc now owns 5,815 shares of the biopharmaceutical company’s stock valued at $152,000 after purchasing an additional 438 shares during the period. Voya Investment Management LLC acquired a new position in Revance Therapeutics in the second quarter valued at $274,000. The Manufacturers Life Insurance Company increased its stake in Revance Therapeutics by 7.5% in the second quarter. The Manufacturers Life Insurance Company now owns 18,304 shares of the biopharmaceutical company’s stock valued at $483,000 after purchasing an additional 1,275 shares during the period. Finally, Ameriprise Financial Inc. increased its stake in Revance Therapeutics by 1.0% in the second quarter. Ameriprise Financial Inc. now owns 22,904 shares of the biopharmaceutical company’s stock valued at $604,000 after purchasing an additional 225 shares during the period. Institutional investors own 77.84% of the company’s stock.
TRADEMARK VIOLATION WARNING: This piece was reported by Stock Observer and is the sole property of of Stock Observer. If you are accessing this piece on another domain, it was stolen and reposted in violation of US and international copyright and trademark law. The original version of this piece can be accessed at https://www.thestockobserver.com/2018/02/06/revance-therapeutics-rvnc-upgraded-to-hold-at-valuengine.html.
Revance Therapeutics Company Profile
Revance Therapeutics, Inc is a clinical-stage biotechnology company. The Company is focused on the development, manufacturing and commercialization of botulinum toxin products for multiple aesthetic and therapeutic indications. Its peptide technology enables delivery of botulinum toxin type A through two investigational drug product candidates, DaxibotulinumtoxinA for Injection (RT002), or RT002 injectable, and DaxibotulinumtoxinA Topical Gel (RT001), or RT001 topical.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Revance Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revance Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.